Clinical Trials Logo

Arteritis clinical trials

View clinical trials related to Arteritis.

Filter by:

NCT ID: NCT05935709 Recruiting - Clinical trials for Giant Cell Arteritis

DANIsh VASculitis Database (DANIVAS)

DANIVAS
Start date: November 10, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and complications and hence guide management strategies to improve disease control and reduce disease and treatment related damage.

NCT ID: NCT05904301 Recruiting - Clinical trials for Rheumatoid Arthritis

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

NAREG
Start date: June 21, 2023
Phase:
Study type: Observational

Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.

NCT ID: NCT05865054 Recruiting - Clinical trials for Giant Cell Arteritis

Vessel Wall Enhancement in Giant Cell Arteritis

VEGA
Start date: July 29, 2020
Phase:
Study type: Observational

The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient diagnosed with giant cell arteritis (GCA; temporal arteritis).

NCT ID: NCT05854927 Not yet recruiting - Clinical trials for Giant Cell Arteritis

Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)

SPARTA
Start date: January 2024
Phase:
Study type: Observational

Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries. Its incidence is estimated at 17.8/100,000 in subjects over 50 years old (and 46/100,000 in subjects over 70 years old). This disease remains a severe pathology due in particular to its vascular, ophthalmological, neurological, cardiac and aortic complications. In case of suspected CAG, management is a real therapeutic emergency. Indeed, only corticosteroid therapy started as early as possible can prevent the occurrence of these complications. The gold standard for the diagnosis of CAG has long been the temporal artery biopsy, but imaging is now considered as a 1st line diagnostic examination for the diagnosis of CAG according to the EULAR 2018 recommendations. Notably, temporal artery MRI has excellent sensitivity and specificity for diagnosis. However, the high diagnostic performance of MRI has been achieved by performing 3D T1 black blood and fat saturation sequences in high resolution (<0.7mm), which are not accessible in all centers in France and worldwide. The realization of identical sequences with a lower resolution could allow a greater generalization of these sequences and improve the diagnostic management of GCA patients, including in non-expert centers. The objective of our study is to investigate the diagnostic performance of several 3D T1 black blood and fat saturation sequences for the diagnosis of GCA.

NCT ID: NCT05749666 Recruiting - Takayasu Arteritis Clinical Trials

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

TOFGCTAK
Start date: January 20, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, double-blinded, single center, randomized clinical trial. It compares the clinical efficacy and safety of thees 2 drugs in the treatment of active Takayasu's arteritis patients.

NCT ID: NCT05749094 Not yet recruiting - Clinical trials for Giant Cell Arteritis

Optic Nerve Sheath Ultrasound in Giant Cell Arteritis

ONS-GCA
Start date: March 2024
Phase:
Study type: Observational

The objectives of this observational cohort study are : 1. To assess the ability of optic nerve (ON), optic nerve sheath diameter (ONSD) and optic nerve sheath thickness (ONST) measured by ultrasound to predict Giant Cell Arteritis. 2. To evaluate changes in ON, ONSD, ONST measurements in patients with confirmed GCA after three months of therapy 3. To assess dynamic changes in ON, ONSD, ONST measurements in patients with relapsing GCA

NCT ID: NCT05720156 Not yet recruiting - Stroke Clinical Trials

Immunomodulatory Effects of PCSK9 Inhibition

INSPIRAR
Start date: March 2024
Phase:
Study type: Observational

Cardiovascular disease (CVD) represents the leading cause of death worldwide. While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also have pleiotropic effects on inflammation. The immunomodulatory effects of these medications are relevant to ASCVD risk reduction given that inflammation plays a central role in atherosclerotic plaque formation (atherogenesis) and influences the development of vulnerable plaque morphology. Patients on statins, however, may have residual inflammation contributing to incident ASCVD despite the potent LDL-lowering effects of statins. While new therapies, such as proprotein convertase subtilisin/kexin type 9 (PSCK9) inhibitors, further reduce incident ASCVD and drastically reduce LDL-C below that achieved by statin therapy alone, PCSK9 inhibitors may also have pleiotropic effects on inflammation. Thus, PCSK9 inhibitors may help reduce arterial inflammation to a level closer to that of patients without ASCVD. This study will apply a novel targeted molecular imaging approach, technetium 99m (99mTc)-tilmanocept SPECT/CT, to determine if residual macrophage-specific arterial inflammation is present with statin therapy and the immunomodulatory effects of PSCK9 inhibition. Given the continued high mortality and morbidity attributable to ASCVD, strong imperatives exist to better understand the immunomodulatory effects of lipid lowering therapies and residual inflammatory risk. This understanding, in turn, will inform the development of new ASCVD preventative and treatment strategies as well as elucidate other indications for established therapies.

NCT ID: NCT05703763 Not yet recruiting - Clinical trials for Giant Cell Arteritis

Applanation Tonometry in the Diagnosis of Giant Cell Arteritis

TAAT
Start date: March 2024
Phase:
Study type: Observational

The objective of this observational prospective cohort study is to assess if: 1. temporal artery stiffness measurement by applanation tonometry may help predict a final diagnosis of new-onset GCA 2. In patients with a diagnosis of GCA, identify if temporal artery stiffness measured by applanation tonometry improves with treatment.

NCT ID: NCT05663333 Recruiting - Clinical trials for Giant Cell Arteritis

Histopathological Analysis of Temporal Artery Biopsy Following Dynamic Full-field Optical Coherence Tomography, a Comparison to Conventional Histopathological Findings in Patients With Suspected Giant Cell Arteritis (DOCTA)

DOCTA
Start date: January 26, 2023
Phase:
Study type: Observational

Giant cell arteritis (GCA) is a type of large vessel granulomatous vasculitis responsible for the inflammation of the aorta and the branches of the external carotid, notably temporal arteries. The diagnosis of GCA relies upon the identification of vasculitis following histopathological analysis of temporal artery biopsy (TAB) showing mononuclear cells infiltration, fragmentation of the internal elastic lamina as well as significant intimal hyperplasia. Apart from its lack of sensitivity, one of the weaknesses of TAB is the delay in obtaining the result due to the time required to prepare the sample for histological analysis. Pursuing the idea to improve TAB performances, our group recently demonstrated the use of full-field optical coherence tomography (FF-OCT) to visualize structural changes associated with the inflammatory processes of GCA. The present work suggests a further use of dynamic FF-OCT on TAB for a direct visualization of the mononuclear cells infiltration to ensure rapid on-site diagnosis of GCA.

NCT ID: NCT05630885 Active, not recruiting - HIV-1-infection Clinical Trials

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

The study is being conducted to determine if cenicriviroc mesylate (CVC) will decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta.